# James S. Wilmott

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-s-wilmott/

## Facts

| Field | Value |
| --- | --- |
| Citations | 62,479 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 87 |
| i10-index | 200 |
| Last Known Institution | The University of Sydney |
| OpenAlex ID | https://openalex.org/A5001606920 |
| ORCID iD | https://orcid.org/0000-0002-6750-5244 |
| Works | 644 |

## Researcher papers

- [Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study](https://scholariq.org/papers/combination-nivolumab-and-ipilimumab-or-nivolumab-alone-in-melanoma-brain/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [The University of Sydney](https://scholariq.org/institutions/the-university-of-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.